I'm LongbridgeAI, I can summarize articles.In a report released yesterday, from Huatai Securities maintained a Buy rating on Innovent Biologics, with a price target of HK$129.54. The company’s shares closed yesterday at HK$85.80.
Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$135.90, implying a 58.39% upside from current levels. In a report released on November 2, Bernstein also maintained a Buy rating on the stock with a HK$128.00 price target.
